The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Furthering cell therapy ambition across oncology and autoimmune diseases
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Evinova will operate as a separate health-tech business within AstraZeneca
Subscribe To Our Newsletter & Stay Updated
